Spotlight Poster Discussion 10 – Thursday, December 9, 2021: 5:00 pm – 6:30 pm CT
  Novel Immunotherapy Approaches
PD10-01 The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer
McArthur HL, Shiao S, Karlan S, Basho R, Amersi F, Burnison M, Mirhadi A, Chung A, Chung CT, Dang C, Richardson H, Giuliano AE, Kapoor N, Larkin B, Godinez H, Dunn SA, Habibi Khameneh N, Knott S, McAndrew P, Mita M, Park DJ, Abaya C, Chen JH, Ly A, Bossuyt V, Ho A. Cedars Sinai Medical Center, Los Angeles, CA; The Angeles Clinic, Cedars-Sinai Medical Center, Los Angeles, CA; Bedford Breast Center, Beverly Hills, CA; Massachusetts General Hospital, Boston, MA.
PD10-02 A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial)
David S, Savas P, Siva S, White M, Neeson MW, White S, Marx G, Cheuk R, Grogan M, Farrell M, Foudoulis J, Dempsey A, Neeson PJ, Bressel M, Loi S. Peter MacCallum Cancer Centre, Melbourne, Australia; Monash Medical Centre, Melbourne, Australia; Austin Health, Melbourne, Australia; Sydney Adventist Hospital Clinical Trials Unit & Integrated Cancer Centre, Wahroonga, Australia; Department of Radiation Oncology, Cancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane, Australia; Trans Tasman Oncology Group, Newcastle, Australia.
PD10-03 BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O)
Schmid P, Nowecki Z, Im S-A, Chung W-P, Lord S, Armstrong A, Ma CX, Huisden R, Stewart R, Kumar R, Schiavon G, Dry H, Nunes A, Jung KH, Park YH. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Internal Medicine, Cancer Research Institute, College of Medicine, Seoul National University Hospital, Seoul National University, Seoul, Republic of Korea; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom; Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO; AstraZeneca, Cambridge, United Kingdom; AstraZeneca, Gaithersburg, MD; AstraZeneca, Waltham, MA; Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
PD10-04 Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)
Hurvitz SA, Boni V, Comen E, Im S-A, Jung KH, Kim S-B, Lee KS, Loi S, Rugo HS, Sonnenblick A, Telli ML, DuPree K, Fasso M, Lin Y-C, Nikanjam M, Schimmoller F, Zhang X, Zhu J, Schmid P. University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; START Madrid CIOCC, Centro Integral Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Seoul National University College of Medicine, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang-si, Republic of Korea; Peter MacCallum Cancer Center, Melbourne, Australia; University of California San Francisco, San Francisco, CA; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel; Stanford Cancer Institute, Stanford University, Palo Alto, CA; Genentech, Inc, South San Francisco, CA; Barts Health NHS Trust - St Bartholomew's Hospital, London, United Kingdom.
PD10-05 Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial
André F, Deurloo R, Chang C-W, Cameron D, Gligorov J, Schneeweiss A, Barrios C, Xu B, Molinero L, Patel S, Liptrot A, Morales L, Miles D, O’Shaughnessy J. Gustave Roussy, Université Paris Sud, Villejuif, France; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Oncology Biostatistics, Genentech, Inc., South San Francisco, CA; University of Edinburgh, Edinburgh, United Kingdom; Medical Oncology Department, Institut Universitaire de Cancérologie Assistance Publique – Hôpitaux de Paris-Sorbonne Université, Paris, France; Division of Gynecologic Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany; Latin American Cooperative Oncology Group, Porto Alegre RS, Brazil; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA; Product Development Oncology, Genentech, Inc., South San Francisco, CA; Product Development Oncology, Oncology, Roche Products Ltd, Welwyn Garden City, United Kingdom; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Mount Vernon Cancer Centre, Northwood, United Kingdom; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.
PD10-06 Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial
Dugo M, Huang C-S, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Anton A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly C, Mariani G, Del Mastro L, Valagussa P, Viale G, Callari M, Gianni L, Bianchini G. IRCCS Ospedale San Raffaele, Milan, Italy; Breast Center, National Taiwan University Hospital, Taiwan, Taiwan; Medical University of Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario de Valencia, Valencia, Spain; IRCCS Azienda ospedaliero Universitaria di Bologna, Bologna, Italy; Oncocyte Corporation, Nashville, TN; AGAPLESION Markus Krankenhaus, Frankfurt am Main, Germany; University Hospital Miguel Servet, Zaragoza, Spain; Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; and Cancer Cluster Salzburg, Salzburg, Austria; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Semmelweis University, Budapest, Hungary; Istituto Europeo di Oncologia, Milan, Italy; Mater Misericordiae University Hospital, Dublin, Ireland; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Italy; Fondazione Michelangelo, Milan, Italy.
PD10-07 Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies
Soliman H, Wolf D, Chien J, Yau C, Campbell M, Magbanua M, Lu R, O'Grady N, Brown-Swigart L, Hirst G, Parker B, Sit L, Asare S, Yee D, DeMichele A, Nanda R, Pusztai L, Berry D, Esserman L, Van't Veer L. Moffitt Cancer Center, Tampa, FL; University of California San Francisco, San Francisco, CA; Quantum Leap Health, San Francisco, CA; ISPY 2 Advocate, San Francisco, CA; University of Minnesota, Minneapolis, MN; University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Yale, New Haven, CT; Berry Consultants, Austin, TX.
PD10-08 Remodeling the inflammatory breast cancer tumor microenvironment to enhance immunotherapy: Novel therapeutic development
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, ThiHanh Phi L, Pearson T, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Iwase T, Shen Y, Zhang X, Tripathy D, Ueno NT. UT MD Anderson Cancer Center, Houston, TX; Institut Paoli-Calmettes, Marseille, France; Baylor College of Medicine, Houston, TX.
PD10-09 Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment
Callari M, Barreca M, Dugo M, Galbardi B, Viganò L, Locatelli A, Licata L, Viale G, Valagussa P, Viale G, Gianni L, Bianchini G. Fondazione Michelangelo, Milan, Italy; IRCCS Ospedale San Raffaele, Milan, Italy; Istituto Europeo di Oncologia, Milan, Italy.
PD10-10 Withdrawn
PD10-11 Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype
Kuemmel S, Gluz O, Reinisch M, Kostara A, Scheffen I, Graeser M, Wuerstlein R, Nitz U, Luedtke-Heckenkamp K, Hartkopf A, Hilpert F, Kentsch A, Ziske C, Depenbusch R, Braun M, Blohmer J, zu Eulenburg C, Christgen M, Bartels S, Kreipe H, Pelz E, Schmid P, Harbeck N. Breast Unit, Clinics Essen-Mitte, Essen, Germany; West German Study Group, Moenchengladbach, Germany; GynOnco Duesseldorf, Duesseldorf, Germany; Breast Center, Dept. OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany; Niels-Stensen-Kliniken Franziskus-Hospital, Georgsmarienhuette, Germany; University Clinics Tuebingen, Department for Senology, Tuebingen, Germany; Breast Center Hamburg at Hospital Jerusalem, Hamburg, Germany; Diakovere Henriettenstift, Dept. for Gynecology, Hanover, Germany; Praxis Dr. H. Forstbauer, C. Ziske, R. Reihs, E. Rodermann, A. Diel, Troisdorf, Germany; Onkodok GmbH, Guetersloh, Germany; Rotkreuz-Clinics Munich, Munich, Germany; Charité - University Medicine Berlin, Dept. of Gynecology with Breast Center, Berlin, Germany; Hanover Medical School, Institute of Pathology, Hanover, Germany; Institute for Pathology, Viersen, Germany; Queen Mary University of London, London, United Kingdom.